 |
23 Diseases |  |
0 Trials |
|
0 Trials |  |
18 News |  |
- | Zyclara (imiquimod) / Mochida, Viatris, Bausch Health, JNJ-39758979 / J&J
Journal: Histamine 2 Receptor Agonism and Histamine 4 Receptor Antagonism Ameliorate Inflammation in a Model of Psoriasis. (Pubmed Central) - Jun 24, 2021
The combination of amthamine and JNJ-39758979 reduced skin inflammation even more pronounced, diminished epidermal hyperproliferation, and inhibited spontaneous scratching behaviour. A combination of histamine 2 receptor agonist and histamine 4 receptor antagonists could represent a new strategy for the treatment of psoriasis.
- || Xeljanz (tofacitinib) / Pfizer
Review, Journal: Oral small molecules for the treatment of atopic dermatitis: a systematic review. (Pubmed Central) - Nov 28, 2019
Preliminary results demonstrate that oral small molecules are an effective treatment option in AD with minimal side effects. Additional randomized studies with larger sample sizes are needed to determine the efficacy and long-term side effects of these novel therapies.
- || JNJ-39758979 / J&J
Clinical, P2a data, Journal: Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of an H R-antagonist (JNJ-39758979) in adults with uncontrolled asthma. (Pubmed Central) - Nov 19, 2019
P2
The findings suggest potential benefit of H R antagonists on lung function and asthma control in eosinophilic asthma patients and warrant further evaluation of this mechanism in asthma with eosinophilic inflammation. NCT00946569.
- JNJ-39758979 / J&J
Phase classification, Enrollment change, Trial withdrawal: A Dose Range Finding Study of JNJ-39758979 in Patients With Active Rheumatoid Arthritis Currently Treated With Methotrexate (clinicaltrials.gov) - Dec 1, 2016
P2b, N=0, Withdrawn, Sponsor: Janssen Research & Development, LLC
NCT00946569. Phase classification: P2 --> P2b | N=325 --> 0 | Terminated --> Withdrawn
- | JNJ-39758979 / J&J
Trial termination: A Study of JNJ-39758979 in Adult Japanese Patients With Moderate Atopic Dermatitis (clinicaltrials.gov) - May 15, 2012
P2, N=88, Terminated, Sponsor: Janssen Pharmaceutical K.K.
Phase classification: P2 --> P2b | N=325 --> 0 | Terminated --> Withdrawn Recruiting --> Terminated; This study was terminated prematurely due to 2 cases of agranulocytosis.
- JNJ-39758979 / J&J
Trial withdrawal: Study of JNJ-39758979 in Symptomatic Adult Patients With Uncontrolled Asthma (clinicaltrials.gov) - May 9, 2012
P2, N=0, Withdrawn, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting --> Terminated; This study was terminated prematurely due to 2 cases of agranulocytosis. Not yet recruiting --> Withdrawn
- | JNJ-39758979 / J&J
Trial termination: A Dose Range Finding Study of JNJ-39758979 in Patients With Active Rheumatoid Arthritis Currently Treated With Methotrexate (clinicaltrials.gov) - May 9, 2012
P2, N=325, Terminated, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Withdrawn Suspended --> Terminated; Study was terminated prematurely due to 2 cases of agranulocytosis in a different clinical trial with this same drug.
- JNJ-39758979 / J&J
Enrollment change: Study of JNJ-39758979 in Symptomatic Adult Patients With Uncontrolled Asthma (clinicaltrials.gov) - May 9, 2012
P2, N=0, Withdrawn, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Suspended --> Terminated; Study was terminated prematurely due to 2 cases of agranulocytosis in a different clinical trial with this same drug. N=480 --> 0
- | JNJ-39758979 / J&J
New P2 trial: A Study of JNJ-39758979 in Adult Japanese Patients With Moderate Atopic Dermatitis (clinicaltrials.gov) - Dec 20, 2011
P2, N=88, Terminated, Sponsor: Janssen Pharmaceutical K.K.
- JNJ-39758979 / J&J
New P2 trial: Study of JNJ-39758979 in Symptomatic Adult Patients With Uncontrolled Asthma (clinicaltrials.gov) - Dec 14, 2011
P2, N=0, Withdrawn, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- | JNJ-39758979 / J&J
Trial completion: A Study to Investigate How JNJ-39758979 May Affect the Plasma Levels of Methotrexate in Rheumatoid Arthritis Participants (clinicaltrials.gov) - Dec 14, 2011
P1, N=21, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
N=480 --> 0 Active, not recruiting --> Completed
- | JNJ-39758979 / J&J
New P2 trial: A Dose Range Finding Study of JNJ-39758979 in Patients With Active Rheumatoid Arthritis Currently Treated With Methotrexate (clinicaltrials.gov) - Nov 24, 2011
P2, N=325, Terminated, Sponsor: Janssen Research & Development, LLC
- | JNJ-39758979 / J&J
New P1 trial: A Study to Investigate How JNJ-39758979 May Affect the Plasma Levels of Methotrexate in Rheumatoid Arthritis Participants (clinicaltrials.gov) - Sep 26, 2011
P1, N=21, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.